US approval for Sanofi’s late-onset Pompe disease med Nexviazyme
9th August 2021 Uncategorised 0The enzyme replacement therapy is designed to target the key mannose-6-phosphate receptor pathway
More: US approval for Sanofi’s late-onset Pompe disease med Nexviazyme
Source: News
